Previously we have demonstrated that two doses of a cytotoxic T lymphocyte (CTL) epitope–
based peptide vaccine of human papillomavirus type 16 (HPV 16) E7 aa 49–57 elicit …

Peptide-based vaccines aimed at the induction of effective T cell responses against
established cancers have so far only met with limited clinical success and clearly need to be …

Abstract Purpose: Dendritic cells (DCs) are characterized by their extraordinary capacity to
induce T-cell responses, providing the opportunity of DC-based cancer vaccination …

Vaccination with a peptide representing a CTL epitope from the human papillomavirus
(HPV) 16 E7 protein induces a specific CTL response that prevents the outgrowth of HPV16 …

The clinical application of synthetic tumor peptide‐based vaccines is currently limited to
patients with specified major histocompatibility complex (MHC) class I alleles. Such logistic …

Objective. The aim of this study was to generate HPV-16 E7 peptide-specific cytotoxic T
lymphocytes (CTLs) in vitro for future adoptive immunotherapy of cervical cancer. Methods …

Several studies have shown that vaccine therapy using dendritic cells (DCs) pulsed with
specific tumor antigen peptides can effectively induce antitumor immunity. Peptide-pulsed …

Cytotoxic T lymphocyte (CTL) peptide epitopes can be used for immunization of mice
against lethal virus infection. To study whether this approach can be successful against virus …

Vaccination of patients with cancer using dendritic cells (DCs) was shown to be effective for
B-cell lymphoma and malignant melanoma. Here we provide evidence that patients with …

When intracellular viral proteins are degraded, only a limited number of peptide epitopes are
capable of eliciting specific CD8+ cellular immune responses for a given human leukocyte …